GlaxoSmithKline said to be eyeing £1 billion plus takeover bid for Theravance Biopharma, reports The Times

Has GlaxoSmithKline given up its pursuit of Aurinia Pharmaceuticals, the US-listed drug developer?

You need to register and sign in to read this content.